Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Finished Goods (2019 - 2025)

Pulmonx (LUNG) has disclosed Finished Goods for 7 consecutive years, with $13.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Finished Goods fell 10.31% to $13.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.9 million, a 10.31% decrease, with the full-year FY2024 number at $14.7 million, down 7.76% from a year prior.
  • Finished Goods was $13.9 million for Q3 2025 at Pulmonx, up from $13.6 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $16.4 million in Q1 2023 to a low of $8.6 million in Q1 2021.
  • A 5-year average of $14.2 million and a median of $14.7 million in 2024 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: surged 90.18% in 2021, then decreased 14.49% in 2025.
  • Pulmonx's Finished Goods stood at $12.0 million in 2021, then skyrocketed by 30.03% to $15.6 million in 2022, then grew by 2.12% to $16.0 million in 2023, then dropped by 7.76% to $14.7 million in 2024, then fell by 5.73% to $13.9 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Finished Goods are $13.9 million (Q3 2025), $13.6 million (Q2 2025), and $14.3 million (Q1 2025).